Developments in Lead Discovery and Drug Design

SMi’s 12th annual conference on Drug Design taking place on the 18th & 19th February 2013 in London will provide attendees with an unparalleled opportunity for debate and problem solving of key challenges currently facing the field.
Nov. 15, 2012 - PRLog -- Focussing on the latest developments in predictive in-silico off-target profiling, Statistical Issues in CADD, Binding Site Solvent Analysis, Structure-Based Lead Discovery and G-protein-coupled receptors. This event will bring together senior representatives from industry and academia.

SMi is pleased to announce that John Mathias, Head of Medicinal Chemistry, Pfizer has confirmed to speak at the upcoming event.

He will be chairing both day one and day two of the event as well as presenting how to use structure- based drug design to identify novel oral & inhaled p38 inhibitors for COPD. He will look at application for structure-based drug design, use of co-crystal structures to guide different design strategies, optimising slo onset/offset binding kinetics to enhance duration of drug action and current clinical development and status and results.


• Computational approaches in polypharmacology and mode-of-action analysis

• Applying CADD to protein therapeutics

• Drug design strategies for anti-virals and combating resistance

Developments in water network perturbation in structure-based drug design

• Discovery of novel inhibitors through structure-based fragment evolution

Data integration and developments in public-private partnerships

For more information visit or alternatively contact Fateja Begum on +44 0207 827 6184
Source:SMi Group
Email:*** Email Verified
Tags:Drug Design, Protein, Pharmacology, In-Silico
Location:United Kingdom
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Daily News
Weekly News

Like PRLog?
Click to Share